Context: Studies of hip fracture complicating diabetes have not considered the effect of premature mortality.
from clinics or administrative databases with limited or incomplete data relating to diabetes and other hip fracture risk factors. Second, no study to date has considered the effect of the competing risk of death on fracture risk in diabetes.
It is now recognized that analysis of estimates of the population risk of age-related disease end points should allow for premature mortality that may supervene before the particular end point occurs during follow-up (5, 6) . In the case of complications of type 2 diabetes, a condition with a high premature mortality rate, allowing for the competing risk of death is likely to lead to an attenuated but more accurate estimate of the magnitude of risk of the end point in question relative to conventional methods of analysis such as Cox proportional hazards modeling. We have recently demonstrated this in the case of dementia that complicates type 2 diabetes (7), whereas analyses of the relationship between conventional risk factors (such as age, renal impairment, and weight loss) and incident fracture have shown the same effect (8) (9) (10) .
In light of these concerns, we have analyzed longitudinal data from the community-based Fremantle Diabetes Study Phase I (FDS1), in which a well-characterized cohort of patients with diabetes has been followed since recruitment from 1993 to 1996. Our aims were (1) to determine the risk of hospitalization for hip fracture and its determinants in FDS1 patients with type 2 diabetes compared with these risks over the same time in matched individuals without diabetes from the same geographical area, and (2) to assess the effect of the competing risk of death on the unadjusted and adjusted risk of hip fracture in FDS1 patients.
Materials and Methods

Patients and approvals
The FDS1 is a longitudinal observational cohort study of residents with known diabetes recruited from an urban community of 120,097 people in the state of Western Australia. Descriptions of recruitment, sample characteristics (including classification of diabetes type), and details of nonrecruited patients have been published (11) . Of 2258 residents with known diabetes identified between 1993 and 1996, 1426 (63%) were recruited, and 1296 had type 2 diabetes. Eligible residents who declined participation were a mean of 1.4 years older than participants, but their sex distribution, the proportion with type 2 diabetes, and their use of blood glucose-lowering therapies were similar (11) . The FDS1 protocol was approved by the Human Rights Committee at Fremantle Hospital, and all subjects gave written informed consent before participation.
Four age-, sex-and zip code-matched residents without diabetes were randomly selected from the study catchment area for each FDS1 participant at the time of FDS1 study entry using the electoral roll. Voting is compulsory for all Australians age 18 years and older in federal and state elections; thus, all adults resident in the FDS1 catchment area should be listed on the electoral roll. The requirement for zip code matching was based on the fact that there are differences in socioeconomic and migrant status between residential districts within the catchment area. These subjects had not been coded as having diabetes at any time in any Western Australia health database before, during, or after the follow-up period. Five of these residents died just before entry into FDS1 by their matched diabetic participant and were therefore excluded. Matches could not be made for 5 young and 4 elderly participants who were also excluded, leaving 1291 type 2 FDS1 participants (99.6%) matched with 5159 residents without diabetes.
Clinical assessment
The assessment of each FDS1 participant at study entry included a comprehensive questionnaire, a physical examination and related investigations, and biochemical testing of fasting blood and urine samples (11) . Details of medical conditions and their management, as well as demographic, socioeconomic, lifestyle, and other data were recorded. Biochemical testing used standard automated methods in a single, nationally accredited laboratory. Baseline complications of diabetes were identified using standardized definitions (12) . Neuropathy was defined using the clinical portion of the Michigan Neuropathy Screening Instrument (13) . Micro-and macroalbuminuria were defined from early morning urine albumin:creatinine ratios, and the estimated glomerular filtration rate (eGFR) was calculated from the serum creatinine (14) . Retinopathy was defined as any diabetes-associated retinal changes in either eye and/or evidence of previous laser treatment on direct/indirect ophthalmoscopy and/or more detailed ophthalmological data in patients assessed for photocoagulation. Patients were classified as having coronary heart disease if there was a history of myocardial infarction, angina, coronary artery bypass grafting, or angioplasty, and as having cerebrovascular disease if there was a history of stroke and/or transient ischemic attack. Peripheral arterial disease was defined as an ankle brachial index # 0.90 or the presence of a diabetes-related lower-extremity amputation (12) . Annual face-to-face FDS1 assessments continued until 2001, but collection of additional morbidity and mortality data has continued through the Western Australia Data Linkage System (WADLS) (15 The HMDC was used to supplement data obtained through FDS1 assessments that related to prevalent/prior disease during the 5 years before study entry as well as to provide the same information for the matched residents without diabetes. We used these data to calculate a Charlson comorbidity index (CCI) (16) for each individual. The CCI includes history of myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, paralysis, renal disease, liver disease, and cancer, but, for the purposes of the current study, we excluded those conditions coded as diabetes-specific chronic complications (ICD-9 Clinical Modification 250 and ICD-10 Australian Modification E10-14 codes) in FDS1 subjects.
Statistical analysis
The computer packages IBM SPSS Statistics 22 (IBM, Armonk, NY) and StataIC 13 (StataCorp, College Station, TX) were used for statistical analysis. Data are presented as proportions, means 6 standard deviations (SDs), geometric means (SD range), or, in the case of variables which did not conform to a normal or log-normal distribution, medians and interquartile ranges. For independent samples, 2-way comparisons for proportions were by Fisher's exact test, by Student t test for normally distributed variables, and by Mann-Whitney U test for nonnormally distributed variables. A 2-tailed significance level of P , 0.05 was used throughout.
Ten-year age-specific incident rates (IRs) of first incident hip fracture and all-cause death for the FDS1 cohort were compared with those derived for the cohort without diabetes, and incident rate ratios (IRRs) were calculated during follow-up to death or the end of December 2012, whichever came first. Ten-year age groups starting at 55 years of age were selected because of the older age at which hip fracture occurs. The unspecified baseline cause-specific hazards for first incident hip fracture and death were calculated in the combined FDS1 and matched residents cohorts (17); cause-specific hazard ratios (csHRs) were calculated through Cox proportional hazards modeling (forward conditional modeling with P , 0.05 for entry and P . 0.10 for removal), and subdistribution hazard ratios (sdHRs) were calculated by Fine and Gray modeling that allows for the competing risk of death (18) . Traditional Cox models are limited by the assumption that the event of interest will eventually occur, and the Fine and Gray model controls for this bias and yields an sdHR, which is the ratio of hazards associated with the cumulative incidence function (or absolute cause-specific risk) under varying values of a given covariate. Because of the presence of covariates strongly associated with age, age was used as the time scale, with left truncation of age at study entry (19) . Given that the cohort without diabetes was deidentified, there were limited variables available for adjustment, namely age, sex, and comorbidities defined by the CCI. The proportional hazards assumption was checked using Schoenfeld residuals, the log-minus-log curves for Cox models, and the log-minus-log curves for the Fine and Gray models.
Baseline risk factors for incident hip fracture and all-cause death were explored in the FDS1 cohort utilizing the wide range of variables available through FDS1 assessments and data linkage. Variables with bivariate P # 0.20 were considered for entry into the multivariate models. Predictors of frequency of incident hip fracture were assessed using Poisson regression. To allow for the skewed distribution of duration of follow-up, an offset variable of the natural logarithm of the total follow-up time for each patient was used in each model.
Results
Baseline characteristics and incident hip fracture rates
The 1291 FDS1 participants had a mean (6 SD) age of 64.0 (6 11.2) years at study entry, 48.7% were males, and the median (interquartile range) diabetes duration was 4.0 (1.0 to 9.0) years. Nineteen (1.5%) had been hospitalized for hip fracture before study entry. During 16,635 patient-years of follow-up from recruitment (mean 6 SD of 12.9 6 6.1 years), 96 (7.4%) were hospitalized with a hip fracture on 104 separate occasions (8 patients had 2 separate hospitalizations for hip fractures), an IR for first and all incident hip fractures of 5.88 [95% confidence interval (CI), 4.76 to 7.18] and 6.25 (95% CI, 5.11 to 7.58) per 1000 patient-years, respectively. The matched group of 5159 people without diabetes had a mean age of 64.0 6 11.2 years at the time of recruitment of their matched FDS1 counterpart, and 48.7% were males. Forty-nine (0.9%) had a history of hip fracture hospitalization before study entry, and 328 (6.4%) were hospitalized for hip fracture on 371 separate occasions (37 had 2, and 3 had 3 separate hospitalizations for hip fracture) during 75,665 patient-years (14.7 6 5.7 years) of follow-up. The corresponding IRs for first and all incident hip fractures were 4.40 (95% CI, 3.94 to 4.91) and 4.90 (95% CI, 4.42 to 5.43) per 1000 patient-years, respectively.
The crude IRRs for first and all incident hip fractures in FDS1 participants vs matched residents without diabetes were 1.33 (95% CI, 1.05 to 1.68; P = 0.013) and 1.28 (95% CI, 1.02 to 1.59; P = 0.029), respectively. Agespecific IRs and IRRs for first incident hip fracture and all-cause death from age 55 years on are summarized in Table 1 . Overall, the rate of first hip fracture was 34% higher in all FDS1 participants than in matched individuals without diabetes. In the case of subgroups, those age 75 to 84 years had the highest and only statistically significant IRR for first hip fracture, with an 80% higher rate in FDS1 participants. The death rate for all age groups was significantly higher for those with type 2 diabetes, but reduced from 87% in those age 55 to 64 years to 60% in those age $ 85 years. Figure 1 illustrates the higher cumulative first hip fracture incidence for patients with type 2 diabetes compared with matched residents without diabetes.
The unadjusted and adjusted Cox model and Fine and Gray model by diabetes status for first incident hip fracture, together with the Cox model of predictors of allcause death for the pooled cohorts with and without
press.endocrine.org/journal/jcemdiabetes, are shown in Table 2 . The proportional hazards assumption was met for both the Cox model and the Fine and Gray model for hip fracture and death (P . 0.06 for Cox models). During 90,808 patient-years (14.1 6 5.9 years) of follow-up, type 2 diabetes was associated with a nonsignificant sdHR for hip fracture of 1.13 and a significant csHR of 1.53. With adjustment for age, sex, and CCI, these hazards increased to 1.21 for the sdHR (still nonsignificant) and decreased to 1.50 for the csHR. The significant csHR for the competing event of death for those with vs without type 2 diabetes decreased from 1.78 to 1.61 after adjustment but was still highly statistically significant.
Predictors of first incident hip fracture in the FDS1 cohort Baseline bivariate analyses for the whole FDS1 cohort by incident hip fracture status are summarized in Table 3 . Compared with those without incident hip fracture, those who fractured a hip during follow-up were more likely to have had a prior hospitalization for hip fracture and to be female, were older at both study entry and at diagnosis of diabetes, had longer diabetes duration, lower body mass index (BMI), higher systolic blood pressure, worse renal function, and more peripheral sensory neuropathy, and they were more likely to have died during follow-up (P # 0.046).
Independent predictors of first incident hip fracture obtained from the Cox model and Fine and Gray model are shown in Table 4 , together with the Cox model for allcause death. During 16,673 patient-years (12.9 6 6.1 years) of follow-up, all-cause death was predicted by sociodemographic, behavioral, and diabetes-related variables, comorbidities, and apolipoprotein E 4,4 genotype. Of these variables, only male sex (but inversely) was also a significant predictor of first incident hip fracture in the Cox model. In the Fine and Gray model, which included both the association of variables with incident hip fracture and with the competing event of death that prevented individuals fracturing their hip, 
Discussion
The present conventionally analyzed incidence data from a large representative population-based sample of 6450 individuals align with the findings of other studies that have assessed the risk of hip fracture in type 2 diabetes. The IRR for first hip fracture in our FDS1 patients compared with age-, sex-and zip code-matched residents without diabetes was 1.33, at the lower end of the range of pooled relative risk estimates of between 1.34 and 1.7 found in published meta-analyses (1-3). The csHR for hip fracture was 1.50 for type 2 diabetes after adjusting for age, sex, and comorbidities defined by the CCI. However, the sdHR was attenuated to nonsignificance at 1.21 after the same adjustment, suggesting a relatively weak association with type 2 diabetes after allowing for the competing risk of death. This latter finding is consistent with the results of studies of other risk factors for hip fracture (8) (9) (10) . The Cox model and the Fine and Gray model for first incident hip fracture in FDS1 patients identified largely similar predictors of incident risk fracture, but these variables differed from the independent determinants found in a Cox model of all-cause death. Our relatively low IRR compared with risk estimates in meta-analyses (1-3) could reflect inclusion of patients without adequate characterization of diabetes type in pooled data. We used a validated algorithm to classify patients as having type 2 diabetes (11), whereas the studies incorporated in the meta-analyses could have unspecified type or may have included patients with type 1 diabetes who have a much higher risk of hip fracture than those with type 2 diabetes (1-3). In addition, there is evidence that white individuals, who comprise almost all patients in meta-analyses, have higher rates of hip fracture than other racial groups (20) . Although the majority of FDS1 patients were white, 1 of 8 were of a non-Europid racial background. Our community-based sample was representative of diabetes in the study catchment area (11) , but some studies included in the meta-analyses involved selected clinic-based cohorts that may have been enriched for more severe disease and thus nonglycemic risk factors for fracture, such as renal impairment and peripheral sensory neuropathy. Hip fractures are more common in females than males in the general population (21) (22) (23) , which reflects the relatively rapid bone loss that occurs in women during and after menopause. Our data also found female sex to be a strong independent risk factor for hip fracture in the pooled cohort as well as the subset of FDS1 patients with type 2 diabetes. The relationship between sex and hip fracture in previous studies of type 2 diabetes has been inconsistent. In the most recent meta-analysis with the greatest number of included studies, there was a similar risk of hip fractures in women and men (2), but some individual studies have shown a female excess, as in the current study (24) . The relationship between BMI and hip fracture risk in patients with type 2 diabetes is complex. A higher BMI appears to be protective against hip fracture in the general population (25) , but patients with type 2 diabetes have an increased risk despite an increased BMI (26) . We found that, consistent with general population studies, a lower BMI was associated with increased risk of incident hip fracture. It is possible that the availability of a wide range of predictive and confounding factors in FDS1 in multivariable analyses circumvented potential model specification bias and thus allowed for more accurate identification of hip fracture risk factors that included female sex and a lower BMI.
We found that insulin use was independently associated with an increased risk of incident hip fracture in FDS1 participants. There have been limited and inconsistent data regarding this association in previous studies (27) . It has been postulated that insulin may have an anabolic action on bone in type 1 diabetes (28), but it is also possible that insulin use in type 2 diabetes is a surrogate of the adverse effects of longer and more severe glycemic exposure on the health of bone and associated tissues such as the microvasculature and nerve supply. Insulin use may also result in an increased risk of hypoglycemia and thus risk of falls (27) . The strong positive association between chronic kidney disease and hip fracture in FDS1 patients reflects renal osteodystrophy and consequent bone fragility (29) . Patients with diabetic nephropathy are also more likely to have other microvascular complications of diabetes, such as peripheral neuropathy and retinopathy or visual impairment, which may increase the risk of falls.
The risk of fracture in patients with type 2 diabetes is underestimated by bone mineral density measurement (1). In addition, fracture risk calculators have not been extensively evaluated in patients with type 2 diabetes, but they appear to be less accurate than when used in the general population (30, 31) . At present, there are no clinical guidelines or reliable prediction tools to assist with fracture risk evaluation in patients with type 2 diabetes. The independent predictors of hip fracture in our community-based patients (female sex, lower BMI, insulin use, and eGFR ,45 mL/min/1.73m
2 ) may assist in the development of diabetes-specific risk calculators. The current study had limitations. We did not measure bone turnover markers and related indicators (32, 33) , and we did not evaluate bone mineral density or bone microarchitecture (34) . However, many other related studies did not have access to these data (1-3). The strengths of our study were its relatively large size and community-based nature, the long follow-up period for incident fractures and mortality, which were ascertained from a well-validated data linkage system, and the availability of detailed phenotypic data other than investigations specific to bone health.
In conclusion, we found that the risk of incident hip fracture in our patients with type 2 diabetes was at the lower end of the range found in other studies employing conventional statistical methods, perhaps reflecting the multiracial, population-based nature of the FDS1 cohort and the validated categorization of diabetes type. However, the risk of hip fracture in our patients with diabetes was attenuated to nonsignificance after allowing for the competing risk of death. We found that strong independent predictors of incident hip fracture identified in general population studies (female sex, lower BMI, and eGFR ,45 mL/min/1.73m
2 ) were also present in our FDS1 patients, with insulin use a likely surrogate for chronic diabetes-specific effects on bone health and risk of falls.
